Ronald Hall

Ronald Hall, PharmD, is an Associate Professor in the Department of Pharmacy Practice at the Texas Tech University Health Sciences Center School of Pharmacy. He serves as program director for the Dose Optimization and Outcomes Research (DOOR) program, which generates evidence for optimizing medication dosing and outcomes in obese patients. His work bridges clinical pharmacy, pharmacokinetics, and health outcomes research to address critical gaps in special population pharmacotherapy.

Education:

• MSCS with distinction: University of Texas Southwestern Medical Center, 2009
• PharmD: St Louis College Pharmacy, 2000
• BS: St Louis College Pharmacy, 1999

Dr. Hall's research centers on pharmacokinetics, health outcomes, pharmacoepidemiology, and evidence synthesis with specific focus on dose optimization for obesity. His DOOR program investigates antimicrobial stewardship, vaccine effectiveness in rheumatoid arthritis, and drug safety using real-world data. His methodology emphasizes retrospective cohort studies, database analyses, and scoping reviews to translate findings into clinical practice guidelines for complex patient populations.

Analysis of his 15 most recent publications (2021-2024) reveals dominant themes in infectious diseases pharmacotherapy and obesity-related dosing challenges. Key trends include antimicrobial optimization in obesity, Clostridioides difficile management, pneumococcal vaccination efficacy, and pharmacovigilance using large databases like Cerner Health Facts and VA records. His work consistently addresses evidence gaps for special populations through rigorous epidemiological methods.

Scientific Awards:

• NIH Clinical Research Scholar (2006)
• P2 Teaching Team of the Year, TTUHSC SOP (2007)
• Young Alumni Award from St. Louis College of Pharmacy (2008)

As DOOR program director, Dr. Hall leads NIH-funded research initiatives and mentors students in pharmacokinetic modeling and outcomes research. His grants focus on antimicrobial dosing optimization, obesity pharmacotherapy, and health outcomes methodology. He has secured significant funding through the NIH Clinical Research Scholar program and institutional awards, supporting his team's work on real-world evidence generation.

The DOOR program operates as a multidisciplinary research hub collaborating with infectious disease specialists, epidemiologists, and data scientists. It utilizes advanced analytical methods including LC-MS/MS quantification, database mining, and pharmacokinetic modeling to develop evidence-based dosing recommendations for obese patients across therapeutic areas.